Tags

Type your tag names separated by a space and hit enter

Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder.
Psychiatry Res. 2007 Jan 15; 149(1-3):195-200.PR

Abstract

The goal of the present work is to assess for the relationship between the timing of clinical improvement and the resolution of depressive symptoms in Major Depressive Disorder (MDD). 182 MDD outpatients (40.5+/-9.7 years; 53.8% female) who responded following an 8-week, 20 mg, open trial of fluoxetine were included in the analysis. The symptoms questionnaire (SQ) and Beck hopelessness scale (BHS) were also administered to 83 and 153 of these patients, respectively. Onset of clinical improvement was defined as a 30% decrease in 17-item Hamilton depression scale (HDRS-17) scores. Controlling for baseline symptom severity, we then assessed for the relationship between the timing of clinical improvement and depressive symptom at endpoint. Earlier clinical improvement in responders predicted lower HDRS-17, BHS, SQ-depression, SQ-anxiety, but not SQ-somatic symptom or SQ-anger/hostility scores at week 8. This was true regardless of whether improvement was defined as a continuous measure (30% decrease in symptom severity), as a dichotomous measure (clinical response occurring in the first two weeks of treatment). In conclusion, earlier clinical improvement with fluoxetine treatment is predictive of greater symptom resolution at endpoint. Further studies exploring the impact of various treatment modalities and placebo on the timing of clinical improvement and symptom resolution in MDD are warranted.

Authors+Show Affiliations

Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. gpapakostas@partners.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

17157390

Citation

Papakostas, George I., et al. "Timing of Clinical Improvement and Symptom Resolution in the Treatment of Major Depressive Disorder." Psychiatry Research, vol. 149, no. 1-3, 2007, pp. 195-200.
Papakostas GI, Petersen T, Sklarsky KG, et al. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res. 2007;149(1-3):195-200.
Papakostas, G. I., Petersen, T., Sklarsky, K. G., Nierenberg, A. A., Alpert, J. E., & Fava, M. (2007). Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Research, 149(1-3), 195-200.
Papakostas GI, et al. Timing of Clinical Improvement and Symptom Resolution in the Treatment of Major Depressive Disorder. Psychiatry Res. 2007 Jan 15;149(1-3):195-200. PubMed PMID: 17157390.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. AU - Papakostas,George I, AU - Petersen,Timothy, AU - Sklarsky,Katherine G, AU - Nierenberg,Andrew A, AU - Alpert,Jonathan E, AU - Fava,Maurizio, Y1 - 2006/12/08/ PY - 2005/10/18/received PY - 2006/01/07/revised PY - 2006/03/01/accepted PY - 2006/12/13/pubmed PY - 2007/4/11/medline PY - 2006/12/13/entrez SP - 195 EP - 200 JF - Psychiatry research JO - Psychiatry Res VL - 149 IS - 1-3 N2 - The goal of the present work is to assess for the relationship between the timing of clinical improvement and the resolution of depressive symptoms in Major Depressive Disorder (MDD). 182 MDD outpatients (40.5+/-9.7 years; 53.8% female) who responded following an 8-week, 20 mg, open trial of fluoxetine were included in the analysis. The symptoms questionnaire (SQ) and Beck hopelessness scale (BHS) were also administered to 83 and 153 of these patients, respectively. Onset of clinical improvement was defined as a 30% decrease in 17-item Hamilton depression scale (HDRS-17) scores. Controlling for baseline symptom severity, we then assessed for the relationship between the timing of clinical improvement and depressive symptom at endpoint. Earlier clinical improvement in responders predicted lower HDRS-17, BHS, SQ-depression, SQ-anxiety, but not SQ-somatic symptom or SQ-anger/hostility scores at week 8. This was true regardless of whether improvement was defined as a continuous measure (30% decrease in symptom severity), as a dichotomous measure (clinical response occurring in the first two weeks of treatment). In conclusion, earlier clinical improvement with fluoxetine treatment is predictive of greater symptom resolution at endpoint. Further studies exploring the impact of various treatment modalities and placebo on the timing of clinical improvement and symptom resolution in MDD are warranted. SN - 0165-1781 UR - https://www.unboundmedicine.com/medline/citation/17157390/Timing_of_clinical_improvement_and_symptom_resolution_in_the_treatment_of_major_depressive_disorder_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165-1781(06)00087-4 DB - PRIME DP - Unbound Medicine ER -